文献速递帕金森病与运动障碍神经免疫

双导联丘脑脑深部电刺激治疗难治性多发性硬化震颤的安全性与疗效

Safety and efficacy of dual-lead thalamic deep brain stimulation for patients with treatment-refractory multiple sclerosis tremor: a single-centre, randomised, single-blind, pilot trial.
PubMed 文献 · Lancet Neurol · 2017-06-20

这项单中心、随机、单盲、先导性试验纳入12例药物难治性多发性硬化震颤成人患者,比较双导联丘脑DBS(VIM导联与VO导联)的安全性和疗效。作者认为双导联丘脑DBS可能是改善严重难治性多发性硬化震颤的安全有效选择,但需更大规模研究验证。

要点

  • 11例可评估患者中3例对手术干预无应答。
  • 常见非严重不良事件为头痛和疲劳,需关注感染等严重不良事件。

核心结论

  • 双导联丘脑DBS可能安全有效地改善严重难治性多发性硬化震颤。
  • 需更大规模研究验证其广泛适用性、长期安全性和对其他严重震颤障碍的疗效。

研究设计与样本

  • 单中心、单盲、前瞻性、随机先导性试验,地点为美国佛罗里达大学运动障碍与神经修复中心。
  • 2007年1月16日至2013年12月17日纳入12例临床诊断多发性硬化震颤且既往药物治疗难治的成人患者。
  • 术前按1:1随机接受3个月优化单导联DBS(VIM或VO),采用计算机生成序列、每4例一组共三组,由中心独立成员分配。
  • 主要结局为术后6个月双导联激活时平均总TRS评分较术前基线的变化,按意向性治疗分析。

主要发现

  • 11例可评估患者中3例对手术干预无应答。
  • 1例VO单导联组患者发生感染需取出DBS装置,被排除于主要结局评估。
  • 1例患者术后2年突然死亡,判定与DBS植入无关。
  • 严重不良事件包括1例表浅伤口感染经抗生素治疗缓解,以及另1例短暂精神状态改变和晚期多发性硬化加重;最常见非严重不良事件为头痛和疲劳。

关键数值与推荐

  • 随机分配为1:1接受3个月优化单导联DBS(VIM或VO),随机化采用计算机生成序列、每4例一组共三组。
  • 6个月随访时在VIM开、VO开、双开、双关四种刺激条件下测量TRS评分并评估情绪与心理量表,每种设置测试4个连续日,测试前刺激设置至少保持恒定12 h。

临床怎么用

  • 对于药物难治性多发性硬化震颤,双导联丘脑DBS(VIM与VO联合)可作为改善震颤的候选干预。
  • 临床决策需权衡感染、短暂精神状态改变和多发性硬化加重等不良事件风险。
  • 该技术尚属先导性探索,需更大规模研究确认长期安全性和广泛适用性后再推广。

局限性

  • 单中心、先导性试验,样本量仅12例,其中1例因感染被排除于主要结局评估。
  • 随访期较短(主要结局为6个月),长期安全性和疗效未确定。
  • 开放标签的DBS编程护士参与实施,部分评估可能存在偏倚;作者指出需更大规模研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Efficacy in previous studies of surgical treatments of refractory multiple sclerosis tremor using lesioning or deep brain stimulation (DBS) has been variable. The aim of this study was to investigate the safety and efficacy of dual-lead thalamic DBS (one targeting the ventralis intermedius-ventralis oralis posterior nucleus border [the VIM lead] and one targeting the ventralis oralis anterior-ventralis oralis posterior border [the VO lead]) for the treatment of multiple sclerosis tremor. METHODS: We did a single centre, single-blind, prospective, randomised pilot trial at the University of Florida Center for Movement Disorders and Neurorestoration clinic (Gainesville, FL, USA). We recruited adult patients with a clinical diagnosis of multiple sclerosis tremor refractory to previous medical therapy. Before surgery to implant both leads, we randomly assigned patients (1:1) to receive 3 months of optimised single-lead DBS-either VIM or VO. We did the randomisation with a computer-generated sequence, using three blocks of four patients, and independent members of the Center did the assignment. Patients and all clinicians other than the DBS programming nurse were masked to the choice of lead. Patients underwent surgery 1 month after their baseline visit for implantation of the dual lead DBS system. A pulse generator and two extension cables were implanted in a second surgery 3-4 weeks later. Patients then received an initial 3-month period of continuous stimulation of either the VIM or VO lead followed by blinded safety assessment of their tremor with the Tolosa-Fahn-Marin Tremor Rating Scale (TRS) during optimised VIM or VO lead stimulation at the end of the 3 months. After this visit, both leads were activated in all patients for an additional 3 months, and optimally programmed during serial visits as dictated by a prespecified programming algorithm. At the 6-month follow-up visit, TRS score was measured, and mood and psychological batteries were administered under four stimulation conditions: VIM on, VO on, both on, and both off (the order of testing was chosen by a computer-generated random sequence, assigned by independent members of the centre, and enacted by an unmasked DBS programming nurse). Each of four stimulation settings were tested over 4 consecutive days, with stimulation settings held constant for at least 12 h before testing. The primary outcome was change in mean total TRS score at the 6-month postoperative assessment with both leads activated, compared with the preoperative baseline mean TRS score. Analysis was by intention to treat. Safety was analysed in all patients who received the surgical implantation except in one patient who discontinued before the safety assessment. This trial is registered with ClinicalTrials.gov, number NCT00954421. FINDINGS: Between Jan 16, 2007, and Dec 17, 2013, we enrolled 12 patients who were randomly assigned either to 3 initial months of VIM-only or VO-only stimulation. One patient from the VO-only group developed an infection necessitating DBS explantation, and was excluded from the assessment of the primary outcome. Compared with the mean baseline TRS score of 57·0 (SD 10·2), the mean score at 6 months decreased to 40·1 (17·6), -29·6% reduction; t=-0·28, p=0·03. Three of 11 patients did not respond to surgical intervention. One patient died suddenly 2 years after surgery, but this was judged to be unrelated to DBS implantation. Serious adverse events included a superficial wound infection in one patient that resolved with antibiotic therapy, and transient altered mental status and late multiple sclerosis exacerbation in another patient. The most common non-serious adverse events were headache and fatigue. INTERPRETATION: Dual lead thalamic DBS might be a safe and effective option for improving severe, refractory multiple sclerosis tremor. Larger studies are necessary to show whether this technique is widely applicable, safe in the long-term, and effective in treating multiple sclerosis tremor or other severe tremor disorders. FUNDING: US National Institutes of Health, the Cathy Donnellan, Albert E Einstein, and Birdie W Einstein Fund, and the William Merz Professorship.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Oliveria SF, Rodriguez RL, Bowers D, et al. Safety and efficacy of dual-lead thalamic deep brain stimulation for patients with treatment-refractory multiple sclerosis tremor: a single-centre, randomised, single-blind, pilot trial. Lancet Neurol. 2017. PMID: 28642125. doi:10.1016/S1474-4422(17)30166-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。